---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-293959"
form_type: "8-K"
ticker: "BCAB"
cik: "0001826892"
company_name: "BioAtla, Inc."
filed_at: "2023-12-13T23:59:59+00:00"
generated_at: "2026-06-07T13:35:57.059824+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BioAtla reports Phase 1 data for BA3071: confirmed responses in solid tumors, safe profile, Phase 2 initiated

## Summary
- Phase 1 dose-escalation of BA3071 (CAB-CTLA-4) in 18 PD-1-failure patients: 2 confirmed responses (1 CR stage IV cervical, 1 PR stage IV gastro-esophageal), 9 stable disease.
- No grade 4 treatment-emergent adverse events; two grade 3 immune-related AEs. Maximum tolerated dose not reached; DLT at 700 mg.
- Durable disease control: uveal melanoma (>12 cycles), cutaneous melanoma (>14, >17 cycles), SCLC (>22 cycles).
- Phase 2 monotherapy and in combination with PD-1 inhibitor is now underway.

## SEC filing metadata
- accession: 0001193125-23-293959
- form_type: 8-K
- ticker: BCAB
- cik: 0001826892
- company_name: BioAtla, Inc.
- filed_at: 2023-12-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826892/000119312523293959/0001193125-23-293959-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826892/000119312523293959/d35885d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-293959
- JSON: https://secwatch.observer/filing/0001193125-23-293959.json
- Plain text: https://secwatch.observer/filing/0001193125-23-293959.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.